Oppenheimer & Co’s Coya Therapeutics COYA Stock Holding History

Oppenheimer & Co’s Portfolio COYA Stock Details COYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-18,000	Closed	-$105K	–	1775
2026 Q2	$105K	Hold	18,000	–	–	﹤0.01%	1719
2026 Q1	$70.9K	Buy	18,000 +4,000	+29%	+$18.7K	﹤0.01%	1655
2025 Q4	$81.2K	Buy	+14,000	New	+$85.1K	﹤0.01%	1501

Other funds holding COYA

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Private Management Group Irvine, California $3.63B AUM 11.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

BFSG LLC Irvine, California $1.14B AUM 21.04% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Oppenheimer & Co's COYA Position: Q3 2026 in Review

Oppenheimer & Co sold out of Coya Therapeutics (COYA) in Q3 2026, closing a stake of 18,000 shares — an estimated $105K sold.

Oppenheimer & Co first reported a position in COYA in Q4 2025 and held it in 3 quarters. The position peaked at $105K in Q2 2026. 14 funds tracked by Wall St. Rank hold COYA as of Q3 2026.

Oppenheimer & Co reported no remaining Coya Therapeutics position as of Q3 2026 after selling out during the quarter.
Oppenheimer & Co sold 18,000 Coya Therapeutics shares in Q3 2026, an estimated $105K.
Oppenheimer & Co first reported a position in Coya Therapeutics in Q4 2025 and held it in 3 quarters.
Oppenheimer & Co's Coya Therapeutics position peaked at $105K in Q2 2026.
14 funds tracked by Wall St. Rank held Coya Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.